We believe the evidence from our study will accelerate efforts to identify novel therapeutics that can optimize CR rates in patients with newly diagnosed MM and provides a compelling rationale for exploring new strategies to upregulate HRP2 expression or target H3K27me3 to restore PI sensitivity in patients with RR MM. Here, HDGFL2 is linked to Miyoshi myopathy.